Field of the Invention
This invention relates generally to medical connectors through which fluids flow, and in particular, to medical connectors with male luers.
Description of the Related Art
Systems of connectors, valves, and tubing are routinely used in hospitals and other medical settings for facilitating the transfer of fluids to and from patients. It is often a challenge to keep such systems sterile and to prevent leakage of fluids when the various components are engaged and disengaged.
In order to maintain a barrier to bacteria, debris, and fluid leakage, female connectors often have been provided with closures, such as septa, flexible seals, or other impediments, at their mating ends. When a male luer connector is engaged with the female connector, the closure of the female connector is temporarily opened, pierced, or moved to allow fluid to flow between the two connectors. Male connectors typically employ needles or luers to open, pierce, or move the closure on the female connectors.
In many systems, only the female connectors are automatically blocked from the external environment when disengaged. Male luer connectors are generally not provided with automatic closing mechanisms. Male luer connectors sometimes employ additional components, such as caps, to stop the flow of fluid and impede the entry of bacteria and debris. Because such closure mechanisms are not automatic (or not used at all), male luer connectors are sometimes left unsealed, allowing fluid to drip out. This may increase the risk of unsanitary conditions inside and outside of the fluid transfer system. In addition, in some medical applications such as certain chemotherapy treatments, the fluids in the tubing and connectors can be harmful if released.
Moreover, in the busy environment of hospitals and other medical settings, health care providers must often quickly manipulate multiple medical implements with one hand, making it difficult to retrieve male luer caps and rapidly attach them upon disengagement of male connectors. In addition, male luer connectors are often employed at the downstream end of gravity-fed fluid sources such as IV bags. When the connectors and tubing are initially connected to such sources, they are generally empty (i.e., filled with air) and must be primed with fluid before they can be connected to a patient. During the priming procedure, fluid is allowed to flow from the upstream end of the tubing toward the male luer connector on the downstream end. As the flow flows through the tubing, the air in the tubing escapes through the male connector on the downstream end into the environment. Once the fluid itself reaches the male connector, it can also escape and spill out. Because male luer connectors do not usually close automatically after priming, the male luer often drips out a small amount of fluid as the male connector is rapidly moved into mating engagement with a female connector. For this reason, the male luer is generally held over a sink or trash can at the end of the priming procedure to contain the dripping fluid.
There is a need for a closable male luer connector that automatically opens when engaged with a female connector and automatically closes when disengaged from such connector to minimize or eliminate dripping during priming and other procedures and to improve the barrier of the fluid transfer system against bacteria and other debris.
Disclosed are various embodiments of medical connectors with closable male luers. It is contemplated that the features of the various embodiments disclosed herein are combinable to form additional embodiments. Such combinations are within the scope of this disclosure.
In an exemplary embodiment, a male luer connector has a main housing with first and second ends. The second end of the housing comprises a male luer and a shroud surrounding at least a portion of the male luer. The shroud has screw threads disposed on an internal wall thereof. A tubular valve member with a fluid pathway is disposed within the housing. The valve member has a tip on its second end. In the region near the tip, a pair of fluid holes is positioned on opposite sides of the valve member. The tip is configured to abut snugly against an internal wall of the male luer in a region at or near the second end of the male luer. The valve member also has a pair of struts directed towards the second end. The struts extend axially through a portion of the housing, and the ends of the struts towards the second end are positioned within a space between the male luer and the shroud on the second end of the housing. A length of medical tubing is connected to the connector. An end of the tubing is attached to the first end of the valve member by adhesive, welding, or some other means. A resilient, elastomeric member extends from a mid-section region on the outside of the housing to a region at or near the first end of the valve member within the housing.
In a substantially closed state, the resilient member is configured to pull the housing and the tubular valve member together along their respective axes. In this state, the tip of the valve member is pressed into close contact with a portion of the internal wall on the second end of the male luer, and fluid flow from the medical tubing through the tubular valve member is impeded. Fluid generally cannot escape through the opening on the second end of the male luer because such opening is blocked by the tip of the valve member.
When a force is applied to separate the valve member from the housing, the resilient member is stretched and the tip of the valve member is displaced in the direction of the first end from the second end of the male luer. This separating force can be applied manually, for example, by grasping the external wall of the housing with two fingers and grasping the tubing adhered to the first end of the valve member with two other fingers, and then moving the fingers in opposite direction. The separating force can also be applied automatically by a different manual action. For example, the action of connecting the male luer to a female end of another medical implement can automatically separate the valve member from the housing. As the advancing end of the female connector proceeds up the screw threads on the second end of the housing of the male luer connector, the female connector makes contact with and exerts a force directed towards the first end against the struts of the valve member. This force moves the valve member towards the first end against the biasing force directed towards the second end exerted by the resilient member. In this opened state, fluid is permitted to flow through the opposing holes, around the tip of the valve member, and out of the connector through the gap between the tip of the valve member and the internal wall on the second end of the male luer. In some embodiments, the valve member is automatically advanced in the direction of the first end when the valve member contacts a fluid conduit (e.g., a spike positioned within a female connector) as the male and female connectors are brought together.
When the separating force is removed, for example, by releasing the manual grip on the housing and the tubing, or by detaching the female connector from the second end of the housing, the resilient member once again draws the housing and the valve member together. This causes the tip on the second end of the valve member to abut closely against a portion of the internal wall in a region near the second end of the male luer, and impedes fluid flow out of the valve.
Also disclosed herein are other features and configurations for the foregoing embodiment, as well as additional embodiments for other connectors with closable male luers. Such embodiments generally include means for permitting or impeding fluid flow through a male luer on a connector, preferably automatically upon connection with a corresponding female connector.
Certain embodiments of this invention will now be discussed in detail with reference to the following figures. These figures are provided for illustrative purposes only, and the invention is not limited to the subject matter illustrated in the figures.
In one aspect of the present inventions, a variety of means are shown for closing the second end of a male luer connector. In some embodiments, these closing mechanisms function to prevent and/or impede fluid from escaping from or entering into the male luer, while allowing fluid flow when the male luer is manually opened or engaged with a corresponding female luer. As used herein, terms such as “closed” or “sealed” should be understood as obstructions or barriers to fluid flow. These terms should not be understood to require that a particular structure or configuration achieves a complete fluid closure in all circumstances.
In
In
The IV delivery system illustrated in
Referring now to
The embodiment illustrated in
Referring now to
The shroud 24 preferably has inner threads 26 on an interior wall that help securely attached the connector 10 in a removable fashion to another medical implement. In other embodiments, the shroud 24 can include other structures or materials for providing a releasable connection, including quick-release mechanisms and other means. The shroud 24 includes a plurality of depressions 31 on an outer surface to assist the user in firmly grasping and twisting the shroud 24 of the housing 23 with the fingers. The depressions 31 have upwardly tapering sidewalls 33 that prevent the fingers from sliding off the connector 10. On an end towards the first end of the connector 10 of each depression 31, the surface of the housing 23 is approximately co-planar with the surface of the depression 31, while on an end towards the second end 14 of the connector 12 of each depression 31, the surface of the housing 23 is offset from, and preferably lies above, the surface of the depression 31. This configuration allows the fingers to comfortably slide in a direction towards the second end 14 of the connector 10 along the housing 23 into a position for gripping or twisting the connector 10. Once the fingers are in the desired position, a tapered wall 33 on an end towards the second end 14 of the connector 10 of the depression 31 resists further movement by the fingers in the direction of the second end 14. A series of depressions 31 extend around substantially the entire outer surface of the shroud so that the user's fingers, when positioned on opposite sides of the connector 10, will likely encounter a depression 31 regardless of the orientation of the connector 10 during use.
In the illustrated embodiment, the tip 22 has a tapered external wall. The diameter of the tip 22 becomes gradually smaller from the base 25 towards the second end 27. The tip 22 includes a hole at its second end 27. At the base 25 of the luer tip 22, an interior hole 35 (see
The interior wall of the luer tip 22 preferably includes a shelf 30 that extends radially inwardly toward the axis of the fluid passageway 28 surrounded by the luer tip 22, making the fluid passageway 28 narrower at its second end 27 than in the region adjacent to the second end 27. In the illustrated embodiment, the surface of the shelf 30 that faces radially inwardly toward the central axis of the connector 10 is tapered in a manner similar to the taper of the outer surface of the tip 22 (see
The middle portion 32 of the housing 23 lies between the shroud 24 and the upper housing 34. As illustrated, the middle portion 32 has a smaller outer diameter than either the shroud 24 or upper housing 34. The middle portion 32 also has two generally rectangular openings 36 disposed on opposite sides of the housing 23 from each other. When the connector 10 is assembled, the middle portion 32 is generally covered by a portion of the resilient member 18 (see, e.g.,
The upper housing 34 is generally split into two wall sections 45a, 45b by two gaps 38 (only one shown in
As shown in
The housing 23 can be constructed from any of a number of different materials. In some embodiments, the housing 23 can be constructed from a relatively rigid material, such as polycarbonate or other polymeric material. The housing 23 and/or valve member 16 of this embodiment, or components of other embodiments, can also be constructed of a hydrophobic material, such as Bayer Makrolon, or any other suitable material.
Referring now to
From near the middle of the valve member 16 to the first end 48 thereof, the fluid passageway 52 comprises a wider region with protrusions 44 along its external surface. Protrusions 44 form two channels 46 (only one is shown in
Near the first end of the valve member 16 and tube 40, a circumferential channel 57 may be formed around the perimeter of the body of the valve member 16. Raised tabs 49 can be formed along the edge of the channel 57 toward the first end of the connector, while the raised middle portion of the valve member 16 can form the edge of the channel 57 toward the second end of the connector. In some embodiments, the raised tabs 49 do not extend evenly about the perimeter of the first end of the valve member 16, but instead have two larger sections that are spaced diametrically from each other.
The amount of material necessary to construct the valve member 16 can be reduced by indentations made in the outer layers of this portion. The tube 40 can have a passage 52 disposed therethrough. This passage 52 preferably extends from a hole at the first end of the valve member 16 to a pair of holes 50 (only one shown in
The tube 40 of the valve member 16 comprises, at its second end, a flange section 58. The flange section 58 preferably extends further in the radial direction than the adjacent portion of the tube 40. In some embodiments, the flange section 58 can be formed of the same or substantially the same material as the rest of the tube 40. The flange section 58 preferably tapers from the first end of the valve member 16 towards the second end of the tube 40. In some embodiments, the taper is formed at a 5-degree angle, and has a substantially identical taper to that of the radially inwardly facing surface of the shelf 30 of the housing 23. Other amounts of taper, or no taper, can also be used.
The valve member 16, like the housing 23 of
The valve member 16 can be manufactured through injection molding. In some embodiments, at least two gates are used to facilitate distribution of molten plastic throughout the mold. Preferably, one gate can be located along one of the sides of the valve member 16 between the end of the struts 42 towards the first end of the connector and the raised tabs 49 and another can preferably be located near the holes 50 in the valve member 16. The locations of the gates are not fixed, however, and other locations on the valve member 16 can be used for gates when injection molding the valve member 16. Constructing both the housing 23 and the valve member 16 of this or other embodiments out of the same material lessens the chance of deteriorated performance of the connector 10 due to thermal expansion/contraction or chemical interaction between the connector 10 and its environment.
Although the valve member 16 of the illustrated embodiment is configured as shown in
As can be seen in the embodiment illustrated in
In the embodiment illustrated in
As shown in
Turning now to
The elastic members 64 can be constructed from a number of elastic materials. In some embodiments, the elastic members 64 are made from a silicon rubber elastic material. In other embodiments, the elastic members 64 can be made from a shape-memory material. In still other embodiments, the elastic members 64 and/or the resilient member 18 can comprise springs or other structures capable of exerting a restoring force.
The rings 60, 62 can also be constructed from a number of materials. In some embodiments, the rings 60, 62 are constructed from the same deformable elastic material that comprises the elastic members 64. Thus, the rings 60, 62 can be stretched into a diameter to extend around the appropriate portion of the housing 23 to which each respective ring 60, 62 is attached. The resilience of the rings 60, 62 can function to effectively hold each ring 60, 62 in place on the housing 23. In other embodiments, the rings 60, 62 can be constructed from rigid or semi-rigid materials, and can, for example, comprise half-circles that can be snapped into and out of position. In some embodiments, the resilient member 18 can be integrated into the valve member 16 or housing 23. In some embodiments, other structures and/or configurations can be used to selectively urge the valve member 16 and the housing 23 together in a different manner than a resilient member 18.
Turing now to
The sealing portion 20 can be constructed from a number of different materials. In some embodiments, the sealing portion 20 is made from a silicon-based deformable material 70. Silicon-based deformable materials are among those that form fluid-tight closures with plastics and other rigid polymeric materials. The sealing portion 20 can be made from the same material as the resilient member 18.
In
Certain interconnections between the various portions of the male luer 10 will now be discussed in further detail. As shown, the smaller ring 62 of the resilient member 18 fits within the circumferential channel 57 of the valve member 16. In some embodiments, the smaller ring 62 can be stretched until it has a larger inner diameter than the raised tabs 49 at the first end of the valve member 16. Once the small ring 62 has been advanced into position about the circular channel 57, it can be released, so that it wraps tightly about the circular channel 57, as shown.
The larger ring 60 of the resilient member 18 extends around the middle portion 32 of the housing 23 (as shown in
The sealing portion 20, which is partially hidden by the resilient member 18 in
A closing mechanism 56 is adapted to close the fluid passage extending through the closable male luer 10 from fluid communication with the external environment, preferably whenever the male luer 10 is not engaged with the female connector 92. In the illustrated embodiment, the fluid passageway 54 comprises the lumen 28 as well as the passage 52 of the valve member 16. The closing mechanism 56 of the illustrated embodiment comprises both the flange section 58 of the tube 40 and the internal taper of the raised portion 30 of the lumen 28. As these two surfaces contact, they can form a closure at or near the second end 20 of the male luer 10.
The substantially matched internal tapering surfaces of the raised portion 58 of the tube 40 and the raised portion 30 of the lumen 28 assist in providing closure of the female connector 92. Preferably a relatively fluid-tight closure is formed. The engagement between the raised portions 30 and 58 can also be created in a number of other ways. In some embodiments, the material of the flange section 58 and the material of the raised portion 30 of the lumen 28 are configured to fit closely together, and are made of sufficiently compatible materials, to form a fluid-tight closure. In other embodiments, the flange section 58, and/or additional portions of the valve member 16, can be constructed from a deformable material that more closely follows the contours of the internal surface of the lumen 28, and the lumen 28 need not have a taper. The sealing portion 20 is configured, in some embodiments, to prevent fluid from escaping from within the male luer connector 10. When the valve member 16 engages the housing 23, the sealing portion 20 sits between the middle portion 32 of the housing 23 and the tube 40. When fluid flows within the lumen 28 of the housing 23 and along the outer surface of the tube 40, the fluid is prevented from flowing past the middle portion 32 by the sealing portion 20, and more particularly by the rings 69 at either end of the sealing portion 20.
The sealing portion 20 is preferably held in position between the housing 23 and valve member 16 by the protrusions 68 (see
With reference to the embodiment illustrated in
As shown in
As shown in
In
As shown in
As the male luer connector 10 and female connector 92 move towards each other into threaded engagement, the proximal end 84 of the tip of the female connector 92 contacts the struts 42 of the valve member 16. As the male luer connector 10 and female connector 92 move further into threaded engagement, the struts 42, and thereby the valve member 16, are moved in the direction of the first end of the male connector by the female connector 92, displacing the valve member 16 relative to the housing 23. Thus, the flange section 58 moves from the second end of the tip 22 of the housing 23 towards the first end of the male connector. As these two tapered surfaces separate, a space forms between the valve member 16 and the housing 23 and fluid is allowed to pass through the hole 30′ into the fluid passageway 74 of the female connector 92, or vice versa. When used with some embodiments of the female connector 92, an internal fluid conduit contacts the second end of the valve member 16 before the housing of the female connector 92 contacts the struts 42 to open the male connector 10. In some embodiments, the closure remains intact until the inner surface 80 of the tip of the female connector 92 has formed a closing engagement with the outer surface of the tip 22 of the male luer 10. Thus, the passage 54 of the male luer 10 need not be in fluid communication with the external environment.
As the valve member 16 moves relative to the housing 23, the elastic members 64 (not shown in
Despite the relative movement between the housing 23 and the valve member 16, the sealing portion 20 preferably maintains a fluid barrier between the outer surface of the tube 40 and the inner surface of the lumen 28. In some embodiments, the position of the sealing portion 20 is maintained by the protrusions 68. In other embodiments, the sealing portion 20 can be positioned by gluing the outer surface of the deformable material 70 to the inner surface of the lumen 28 of the housing 23. Other means of fixing the sealing portion 20 can also be used.
As shown in
Turning to
With reference to
As the luer tip 22 advances further into the closeable female connector 210, the fluid conduit 216 contacts the end of the valve member 16 towards the second end of the male connector. The valve member 16 is displaced towards the first end of the male connector by the contact and continued advancement of the luer tip 22. The resilient member 18 exerts a closing force in a direction towards the second end of the male connector on the valve member 16. As a result, the tip of the valve member 16 towards the second end of the male connector generally maintains contact with the fluid conduit 216 throughout the engagement. As the valve member is moved in a direction towards the first end of the male connector, the flange section 58 of the valve member 16 separates from the interior surface of the housing 23 through which the hole 30′ passes. As a result, the windows 50 are opened to fluid communication with the closeable female connector 210. The compressed seal element 214 inhibits fluid flow into the interior of the closeable female connector 210 beyond the luer tip 22. In this configuration, fluid can flow from the tubing 13 at the end of the valve member 16 toward the second end of the male connector and into the tube 40 through the windows 50 into the interior of the lumen 28, out the hole 30′ in the luer tip 22, into the interior of the outer housing 213 of the closeable female connector 210, in the holes 215 of the fluid conduit 216 and into the fluid channel 217 in the interior of the fluid conduit 216. Thus, the second end of the connector 210 is placed in fluid communication with the proximal end 219 of the closeable female connector 210. Additionally, the sealing portion 20 preferably maintains a fluid barrier between the outer surface of the tube 40 and the inner surface of the lumen 28, confining the flow of fluid towards the closeable female connector 210. When the surface of the valve member towards the second end of the connector is directly contacted by a female connector member such as the fluid conduit 216, the struts 42 may not be engaged by the female connector.
The connectors 10, 210 can be threadedly disengaged. During engagement, the force exerted by the resilient member 18 can return the connector 10 to its pre-engaged state by directing the valve member 16 to engage the flange section 58 of the end of the valve member 16 toward the second end of the male connector with the internal surface of the luer tip 22. Likewise, the resilient material of which the compressible seal is composed can return to its shape in the closed position and the proximal surface 217 can seal the proximal tip of the closeable female connector 210.
Referring now to
With reference now to
Turning to
Referring to
With reference to
In
The luer tip 256 of the syringe 250 protrudes into the tube 40 of the valve member 16. The reservoir 260 of the syringe 250 is in fluid communication with the tube 40 of the valve member 16 through the luer tip 256.
The connector 10 is engaged with the needle with a sheath 270. The housing 266 of the needle with sheath 270 has raised tabs 264 near its proximal end. The raised tabs 264 threadedly engage the inner threads 26 of the shroud 24 of the connector 10. As the luer tip 22 advances into the housing 266 of the needle 268, the proximal end of the housing 266 can contact the struts 42 of the valve member 16. When the needle with sheath 270 is fully engaged with the connector 10, the valve member 16 has been displaced a distance which separates the flange section 58 from the tapered interior wall of the lumen 28 sufficiently to permit fluid to flow out the windows 54 of the valve portion 16. The fluid can then flow out the hole 30′ in the end of the luer tip 22 and into the housing 266 of the needle with sheath 270. The hollow needle 268 permits the fluid to flow from within the housing 266 out the distal tip of the needle 268. The sealing portion 20 preferably maintains a fluid barrier between the outer surface of the tube 40 and the inner surface of the lumen 28, confining the fluid in the lumen and the direction of flow toward the hole 30′ in the luer tip 22. Thus, at this stage, the syringe 250 is in fluid communication with the distal tip of the needle 268. As was previously illustrated in
The housing 310 illustrated is configured to receive a male luer tip at the luer receiver 316 by threadedly engaging the male luer at its engagement portion 318. The receiver 316 can conform to ANSI standards for a luer receiver. The illustrated manipulation portion 320 has two tabs extending radially from the central axis of the housing 310. The manipulation portion 320 is configured to aid the user in grasping and rotating the connector 300.
The housing 310 illustrated is also constructed to provide a closeable male luer at its second end. The luer tip 312 at the second end can be constructed to ANSI standards for a male luer tip. The luer tip joins the main body of the housing 310 at the raised portion 340. The raised portion 340 is constructed to inhibit the luer tip 312 from advancing too far into a luer receiver. The housing 310 can also have a recessed portion 342 behind the raised portion 340. The luer tip 312 can also have a seal element 330 which has a face 314 towards the second end of the connector. The seal element 330 can be any water-impermeable, resilient material, including without limitation, silicone. The selection of the material for construction of the seal can be accomplished by one skilled in the art. The luer tip 312 can taper smaller in a direction from the raised portion 340 as it approaches its second end.
The seal element 330 can also have an opening 350 in the face 314 toward the second end of the connector prior to engagement with any other component. The opening 350 can be a slit in a transverse direction to the longitudinal axis of the housing 310. The opening 350 can be centered across the face 314, or located in another position on the face 314. The seal element 330 can cover the entire second end of the luer tip 312, or only a portion thereof. The seal element 330 can be attached to the housing by an overmolding process, among other attachment methods. In such an overmolding process, the housing 310 can be formed by injection molding in a first step, and then in a second step, the housing 310 can be re-inserted into a mold (or remain in a mold) and an appropriately sized molding pin (not shown) can be inserted through a wider end of the housing 310, such as the second end. Silicone material can then be injected into the mold to form the seal element 330. In other embodiments, the seal element 330 can be glued or otherwise adhered into the housing 310.
As can be seen from the illustrated embodiment in
In some modes of use, the opening 350 on the face 314 of the seal element 330, normally closed in the position shown, can be opened when the luer tip 312 comes in contact with a suitable female connector, such as a Clave® connector sold by ICU Medical, San Clemente, Calif. An illustrated engagement of this configuration is discussed in detail below. The engagement can be achieved in many other ways, and with many other structures, including connectors other than the Clave connector.
As can be seen in
Referring now to
Certain medications, such as chemotherapy medications, are contact toxins, and avoiding exposure to the skin is desirable. Such medications are often stored in a syringe with a hypodermic needle, such as depicted in
Referring now to
With reference now to
With reference to
Turning to
As can be seen in
With reference now to
Referring now to
Turning to
With reference now to
Referring to
The flexible segment 752 permits the user to orient the female connector 750 of the assembly 725 in a different attitude than that of the closeable male luer connector 700. As an example, the closeable male luer 700 can remain stationary against a patient's arm while the female connector 750 is angled away from the arm to assist in easy connection with a syringe or other component (not shown). By flexibly connecting the closeable male luer 700 to the female luer connector 750, the moment generated by moving the female luer connector 750 is accepted at a point between the two components of the assembly 725 and is less likely to be transmitted to another component (not shown) attached to the closeable male luer connector 700. Such a component could include an I.V. site, where angling of the connection could result in harm to the patient. Moreover, the moment will be less likely to bend and/or dislodge the tip of the tube 40 from the interior of the lumen 28 (see, e.g.,
As illustrated in
As discussed above, the region 928 and the female end 904 of the housing 906 can be structured to include one or more of the components of the closing female end of connectors 21, 210 (and/or any components from other types of closing female connectors) to permit the female end 904 of the connector 910 to be selectively opened or closed to fluid flow.
An internal conduit 932 can partially or completely surround the region 924 of the internal fluid passageway 916. The conduit 932 can be secured to a base 934, and the base 934 can be secured to the female end 904 on one side and to an intermediate portion 936 on the other side. In the illustrated embodiment, the outer perimeter of the base 934 extends to the outer perimeter of the housing 906, but it can be configured in many other ways. The intermediate portion 936 can be secured to the remainder of the housing 906. On the end of the valve member distal from the male end 902, an internal conduit 938 can surround region 922 of the fluid passageway 916. In the illustrated embodiment, the internal conduit 938 of the valve member is larger in cross-sectional area and in internal volume than is the internal conduit 932 surrounding region 924. A seal element 940 can be positioned in a region of interface between internal conduits 932, 938 to prevent or minimize leakage of fluid out of the passageway 916 at such interface, while permitting relative axial movement between internal conduits 932, 938. In some embodiments, internal conduits 932, 938 are rigid and do not flex or bend under normal operating conditions. In some embodiments, outer housing portions 906, 908, 934, and 936 are molded into a single, contiguous housing. In other embodiments, they may be molded separately and later joined together to form the housing.
As shown in
As illustrated in
In some embodiments, upon disconnection of the medical implement 946 from the connector 900, the male end 902 can automatically close when the valve member 912 moves within the housing 906 toward the male end under the biasing force of the resilient element 910. In certain circumstances, the movement of a valve member within a fluid passageway could push a small volume of fluid within the male end through the male opening and outside of the connector, resulting in a drip induced by the closing of the valve. However, in the illustrated embodiment, such a drip is generally prevented or minimized.
As shown in
In some embodiments, the growing void in region 922 cannot be filled by fluid between region 922 and the syringe or other medical implement 942 because the movement of such fluid is prevented by structures in the medical implement 942 (such as the stem seal within the syringe, not shown). Moreover, in some embodiments, such as that shown in
As a result of the void in region 922, fluid between the valve member 912 and the internal wall of the male end 902 is pulled back within the body of the connector 900 toward region 922 rather than being pushed out of the male opening. As the connector 900 closes, the increasing volume in the interior of the connector 900 tends to draw fluid in from the opening 948 rather than permit the fluid to be expelled. In the illustrated embodiment, this is achieved in part by providing a cross-sectional area of the region 922 that is substantially larger than the cross-sectional area of opening 948. The volume in region 922 increases faster than the volume in 948 decreases as the valve member 912 moves into the closed position. In some embodiments, the rigid walls of the overlapping internal conduits 938, 932 can sustain extended repeat movement and usage with minimal wear. The walls of the overlapping internal conduits 938, 932 generally do not deform or weaken, which could otherwise affect the size of the void created inside of the connector during closure. Moreover, the walls of the overlapping internal conduits 938, 932 generally do not bulge or buckle under relatively high fluid pressures within the connector, nor do they generally permit the valve member 912 to become misaligned within the internal cavity of the housing 906 under most conditions.
In some embodiments of a closeable male luer connector disclosed herein, it may be difficult to “prime” the connector (i.e., replace air inside of the connector with fluid) without forcing air into one or more medical implements to which the connector is attached. In such embodiments, a separate priming cap can be attached to the male end of the connector. The priming cap can be structured in many different ways.
The actuator 925b, or some other structure for manual opening and closing of the connector 900b, can be particularly advantageous in some applications during priming of the closeable male luer connector 900b. It allows for the connector 900b to be opened while air within the connector 900b is evacuated into the environment before the connector 900b is attached to another implement (which would otherwise cause the evacuated air to be forced into such other implement). A priming cap may not be necessary when manual means are provided for opening and closing the connector 900b.
As shown in
In the closed position of the illustrated embodiment, the second end 969e of poppet 963e is positioned in the passage 930e between region 922e and the region 928e of the female end 904e. In many circumstances, the flow of fluid is blocked or diminished between the female end 904e into the interior of the connector 900e due to the close peripheral fit between the second end 969e of the poppet 963e and the passage 930e. However, when the valve member 912e is advanced toward the female end 904e, at least a portion of the second end 969e of the poppet 963e moves out of the passage 930e and in the direction of the female end 904e, enabling fluid communication between the female end 904e and the interior of the connector 900e. When the valve member 912e is returned to its original closed position, the poppet 963e returns approximately to its original position within the region 922e and the second end 969e is positioned within the passage 930e, once again preventing or impeding fluid flow between the female end 904e and the interior of the connector 900e. The second end 969e may include one or more flanges (not shown) extending in the direction of the male end 902e of the connector 900e. These flanges would at least partially remain within the passage 930e when the connector 900e is in the opened position to assist maintaining the axial alignment of the poppet 963e. As the valve member 912e returns to its original position, fluid flow between the female end 904e and the interior of the connector 900e is generally impeded as soon as the second end 969e moves into passage 930e, preferably before the end 913e of the valve member 912e engages the opening 948e of the male end 902e of the connector 900e. With fluid flow in the region 922d in the direction of the female end 904d of the connector 900d impeded, fluid is preferably drawn from the male end 902d and into the expanding region 922d. Many other structures and configurations can be used to accomplish the selective communication of fluid between the female end 904e and the interior of the connector 900e.
As described above, some medications, including those used during chemotherapy, can be harmful in certain forms of exposure to a patient. For example, exposure to the skin can sometimes result in a chemical burn. Inhalation of aerosolized forms of some medications can be harmful. Thus, control over the containment of the medication is highly desirable.
At present, some potentially harmful medications are distributed in sealed vials. The medication is removed from the vial by inserting a needle, and drawing the medication into a syringe. The needle is then withdrawn from the vial and the medication can be dispensed. However, by inserting the needle into the medication for drawing into the syringe, medication is disposed on the outside of the needle, which can inadvertently come in contact with the skin and cause harm. Alternatively, an injector which penetrates the vial with a withdrawal mechanism can be used. In such an injector, the medication is drawn through the mechanism and passed directly to a needle for injection without the additional step of withdrawing the mechanism from the vial. Even if such an injector is used, there is still the possibility of latent medication remaining on the needle used to inject the medication, or on the mechanism after the vial is decoupled.
Additionally, some medications can be distributed by attaching a needle to a syringe with the medication located therein. The engaged syringe with medication and needle is sterilized and placed into a vacuum-sealable container. The container is then evacuated and sealed. This type of arrangement can result in the draw of medication out through the syringe when the container is evacuated. While in the sealed container, the medication may aerosolize or coat the outer surface of the components.
Additionally, when the ambient atmospheric pressure of the treatment location is different, particularly lesser, than that of the internal pressure of the medication within a container, there is the possibility that an uncontrolled spray of the medication occurs when fluid communication between the medication and the ambient atmosphere occurs. For example, medication may escape when a vial with a greater internal pressure than the ambient atmosphere is penetrated by a needle for drawing the medication into a syringe. Alternatively, medication may escape when the needle is withdrawn from the vial before the vial seal completely closes.
With a closeable male luer, flow of the medication out of a syringe with a needle is inhibited, except during desired application. For example, in some embodiments, a syringe with a closeable male luer connected will not leak medication when packaged for shipment, even if the package is vacuum-sealed. Once the package is opened, the male luer connector can be engaged with a female luer connector of an IV tube, for example, and the medication dispensed only when the connection is engaged. Following flow of the medication from the syringe through the engaged connectors and into the IV tube, the male luer connector can be disengaged from the female luer connector. As described above, the male luer connector can close on disengagement, preventing excess flow through the connector. When a closeable female luer connector, such as a Clave® connector sold by ICU Medical, San Clemente, Calif., is used, flow is inhibited from exiting the female connector as well.
Additionally, a syringe with a closeable male luer can be engaged with a needle as described above. Flow through the needle can thus be controlled by proper use of the closeable male luer connector.
Medication can also be disposed within a syringe with an integrally formed, and/or permanently attached, closeable male luer.
Thus, direct exposure of the dangerous medications described can be essentially limited to the highly controlled environments where the medications are produced and contained. Such medications can be placed in a syringe with a closeable male luer connector prior to distribution for use, minimizing the risk of inadvertent exposure of the medication during use of the medication.
Any features of the embodiments shown and/or described in the figures that have not been expressly described in this text, such as distances, proportions of components, etc. are also intended to form part of this disclosure. Additionally, although this invention has been disclosed in the context of various embodiments, features, aspects, and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses of the invention and obvious modifications and equivalents thereof. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with, or substituted for, one another in order to perform varying modes of the disclosed inventions. Moreover, any component or combination of components disclosed herein can be used in other structures or configurations of medical connectors. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a proper reading of the claims.
This application is a continuation application of U.S. patent application Ser. No. 15/499,740, filed Apr. 27, 2017, pending, which is a continuation application of U.S. patent application Ser. No. 15/091,484, filed Apr. 5, 2016, now U.S. Pat. No. 9,636,492, which is a continuation application of U.S. patent application Ser. No. 14/329,372, filed Jul. 11, 2014, now U.S. Pat. No. 9,358,379, which is a continuation application of U.S. patent application Ser. No. 13/534,663, filed Jun. 27, 2012, now U.S. Pat. No. 8,777,908, which is a continuation application of U.S. patent application Ser. No. 12/893,789, filed Sep. 29, 2010, now U.S. Pat. No. 8,211,069, which is a continuation application of U.S. patent application Ser. No. 11/482,176, filed Jul. 6, 2006, now U.S. Pat. No. 7,815,614, which claims priority to U.S. Provisional Application No. 60/696,894, filed Jul. 6, 2005, and to U.S. Provisional Application No. 60/707,319, filed Aug. 11, 2005. The disclosures of the above listed applications are all hereby incorporated by reference in their entireties as if part of this disclosure.
Number | Name | Date | Kind |
---|---|---|---|
2254997 | Fisher | Sep 1941 | A |
2456045 | Brock | Dec 1948 | A |
2842382 | Franck | Jul 1958 | A |
2931668 | Baley | Apr 1960 | A |
2968497 | Treleman | Jan 1961 | A |
3127892 | Bellamy, Jr. et al. | Apr 1964 | A |
3304047 | Martin | Feb 1967 | A |
3334860 | Bolton, Jr. | Aug 1967 | A |
3707972 | Villari et al. | Jan 1973 | A |
3729031 | Baldwin | Apr 1973 | A |
3824556 | Berkovits et al. | Jul 1974 | A |
3986508 | Barrington | Oct 1976 | A |
4055179 | Manschot et al. | Oct 1977 | A |
4066067 | Micheli | Jan 1978 | A |
4076285 | Martinez | Feb 1978 | A |
4080965 | Phillips | Mar 1978 | A |
4084606 | Mittleman | Apr 1978 | A |
4121585 | Becker, Jr. | Oct 1978 | A |
4133441 | Mittleman et al. | Jan 1979 | A |
4143853 | Abramson | Mar 1979 | A |
4150845 | Kopacz et al. | Apr 1979 | A |
4187848 | Taylor | Feb 1980 | A |
4195632 | Parker et al. | Apr 1980 | A |
4233982 | Bauer et al. | Nov 1980 | A |
4245635 | Kontos | Jan 1981 | A |
4324239 | Gordon et al. | Apr 1982 | A |
4334551 | Pfister | Jun 1982 | A |
4340049 | Munsch | Jul 1982 | A |
4379458 | Bauer et al. | Apr 1983 | A |
4387879 | Tauschinski | Jun 1983 | A |
4397442 | Larkin | Aug 1983 | A |
4430073 | Bemis et al. | Feb 1984 | A |
4436125 | Blenkush | Mar 1984 | A |
4457749 | Bellotti et al. | Jul 1984 | A |
4511359 | Vaillancourt | Apr 1985 | A |
4538836 | Kruetten | Sep 1985 | A |
4576359 | Oetiker | Mar 1986 | A |
4610469 | Wolff-Mooij | Sep 1986 | A |
4619640 | Potolsky et al. | Oct 1986 | A |
4623332 | Lindmayer et al. | Nov 1986 | A |
4629159 | Wellenstam | Dec 1986 | A |
4660803 | Johnston et al. | Apr 1987 | A |
4662878 | Lindmayer | May 1987 | A |
4673400 | Martin | Jun 1987 | A |
4700744 | Rutter et al. | Oct 1987 | A |
4723603 | Plummer | Feb 1988 | A |
4723948 | Clark et al. | Feb 1988 | A |
4728075 | Paradis | Mar 1988 | A |
4745950 | Mathieu | May 1988 | A |
4758023 | Vermillion | Jul 1988 | A |
4774964 | Bonaldo | Oct 1988 | A |
4774965 | Rodriguez et al. | Oct 1988 | A |
4781702 | Herrli | Nov 1988 | A |
4804015 | Albinsson | Feb 1989 | A |
4816024 | Sitar et al. | Mar 1989 | A |
4819692 | Olson et al. | Apr 1989 | A |
4834271 | Litwin | May 1989 | A |
4844512 | Gahwiler | Jul 1989 | A |
4862913 | Wildfang | Sep 1989 | A |
4863201 | Carstens | Sep 1989 | A |
4883483 | Lindmayer | Nov 1989 | A |
4915687 | Sivert | Apr 1990 | A |
4917669 | Bonaldo | Apr 1990 | A |
4935010 | Cox et al. | Jun 1990 | A |
4949745 | McKeon | Aug 1990 | A |
4950260 | Bonaldo | Aug 1990 | A |
D313277 | Haining | Dec 1990 | S |
D314050 | Sone | Jan 1991 | S |
5006114 | Rogers et al. | Apr 1991 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5047021 | Utterberg | Sep 1991 | A |
5065783 | Ogle, II | Nov 1991 | A |
5066286 | Ryan | Nov 1991 | A |
5070885 | Bonaldo | Dec 1991 | A |
5083819 | Bynum | Jan 1992 | A |
5098385 | Walsh | Mar 1992 | A |
5108376 | Bonaldo | Apr 1992 | A |
5122123 | Vaillancourt | Jun 1992 | A |
5139483 | Ryan | Aug 1992 | A |
5147333 | Raines | Sep 1992 | A |
5154703 | Bonaldo | Oct 1992 | A |
5176406 | Straghan | Jan 1993 | A |
RE34223 | Bonaldo | Apr 1993 | E |
5199948 | McPhee | Apr 1993 | A |
5201717 | Wyatt et al. | Apr 1993 | A |
5201725 | Kling | Apr 1993 | A |
5203775 | Frank et al. | Apr 1993 | A |
5211634 | Vaillancourt | May 1993 | A |
5215537 | Lynn et al. | Jun 1993 | A |
5215538 | Larkin | Jun 1993 | A |
5242393 | Brimhall et al. | Sep 1993 | A |
5242425 | White et al. | Sep 1993 | A |
5251873 | Atkinson et al. | Oct 1993 | A |
5269771 | Thomas et al. | Dec 1993 | A |
5273533 | Bonaldo | Dec 1993 | A |
5279571 | Larkin | Jan 1994 | A |
5281206 | Lopez | Jan 1994 | A |
5284475 | Mackal | Feb 1994 | A |
5295657 | Atkinson | Mar 1994 | A |
5301686 | Newman | Apr 1994 | A |
5306243 | Bonaldo | Apr 1994 | A |
5312377 | Dalton | May 1994 | A |
5324270 | Kayan et al. | Jun 1994 | A |
5330450 | Lopez | Jul 1994 | A |
5334159 | Turkel | Aug 1994 | A |
5344414 | Lopez et al. | Sep 1994 | A |
5360413 | Leason et al. | Nov 1994 | A |
5370636 | Von Witzleben | Dec 1994 | A |
5380306 | Brinon | Jan 1995 | A |
5385372 | Utterberg | Jan 1995 | A |
5390898 | Smedley et al. | Feb 1995 | A |
5391150 | Richmond | Feb 1995 | A |
5395348 | Ryan | Mar 1995 | A |
5397314 | Farley et al. | Mar 1995 | A |
5400500 | Behnke et al. | Mar 1995 | A |
5401245 | Haining | Mar 1995 | A |
5402826 | Molnar et al. | Apr 1995 | A |
5402982 | Atkinson et al. | Apr 1995 | A |
5405323 | Rogers et al. | Apr 1995 | A |
5405331 | Behnke et al. | Apr 1995 | A |
5405333 | Richmond | Apr 1995 | A |
5411499 | Dudar et al. | May 1995 | A |
5417673 | Gordon | May 1995 | A |
5423791 | Bartlett | Jun 1995 | A |
5425465 | Healy | Jun 1995 | A |
5433330 | Yatsko et al. | Jul 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5441487 | Vedder | Aug 1995 | A |
5445623 | Richmond | Aug 1995 | A |
5447177 | Ricken et al. | Sep 1995 | A |
5456668 | Ogle, II | Oct 1995 | A |
5456675 | Wolbring et al. | Oct 1995 | A |
5462255 | Rosen et al. | Oct 1995 | A |
5464399 | Boettger | Nov 1995 | A |
5470319 | Mayer | Nov 1995 | A |
5470327 | Helgren et al. | Nov 1995 | A |
5474536 | Bonaldo | Dec 1995 | A |
5480393 | Bommarito | Jan 1996 | A |
5489274 | Chu et al. | Feb 1996 | A |
5492147 | Challender et al. | Feb 1996 | A |
5501426 | Atkinson et al. | Mar 1996 | A |
5507744 | Tay et al. | Apr 1996 | A |
5514177 | Kurz et al. | May 1996 | A |
5518026 | Benjey | May 1996 | A |
5520665 | Fleetwood | May 1996 | A |
5520666 | Choudhury et al. | May 1996 | A |
5527284 | Ohnemus et al. | Jun 1996 | A |
5533708 | Atkinson et al. | Jul 1996 | A |
5533983 | Haining | Jul 1996 | A |
5533996 | Murphey et al. | Jul 1996 | A |
5535785 | Werge et al. | Jul 1996 | A |
5540661 | Tomisaka et al. | Jul 1996 | A |
5549566 | Elias et al. | Aug 1996 | A |
5549577 | Siegel et al. | Aug 1996 | A |
5549651 | Lynn | Aug 1996 | A |
5552118 | Mayer | Sep 1996 | A |
5555908 | Edwards et al. | Sep 1996 | A |
5569235 | Ross et al. | Oct 1996 | A |
5573516 | Tyner | Nov 1996 | A |
5575769 | Vaillancourt | Nov 1996 | A |
5578059 | Patzer | Nov 1996 | A |
5584819 | Kopfer | Dec 1996 | A |
5591137 | Stevens | Jan 1997 | A |
5591143 | Trombley, III et al. | Jan 1997 | A |
5597536 | Mayer | Jan 1997 | A |
5616129 | Mayer | Apr 1997 | A |
5616130 | Mayer | Apr 1997 | A |
RE35539 | Bonaldo | Jun 1997 | E |
5643224 | Szapiro et al. | Jul 1997 | A |
5645538 | Richmond | Jul 1997 | A |
5651776 | Appling et al. | Jul 1997 | A |
5674206 | Allton et al. | Oct 1997 | A |
5676346 | Leinsing | Oct 1997 | A |
5685866 | Lopez | Nov 1997 | A |
5685868 | Lundquist | Nov 1997 | A |
5699821 | Paradis | Dec 1997 | A |
5700248 | Lopez | Dec 1997 | A |
5702374 | Johnson | Dec 1997 | A |
5735826 | Richmond | Apr 1998 | A |
5738144 | Rogers | Apr 1998 | A |
5749861 | Guala et al. | May 1998 | A |
RE35841 | Frank et al. | Jul 1998 | E |
5782816 | Werschmidt et al. | Jul 1998 | A |
5784750 | Sankovic et al. | Jul 1998 | A |
5785693 | Haining | Jul 1998 | A |
5788215 | Ryan | Aug 1998 | A |
5806831 | Paradis | Sep 1998 | A |
5810398 | Matkovich | Sep 1998 | A |
5814024 | Thompson et al. | Sep 1998 | A |
5820601 | Mayer | Oct 1998 | A |
5820614 | Erksine et al. | Oct 1998 | A |
5830189 | Chang | Nov 1998 | A |
5839715 | Leinsing | Nov 1998 | A |
5848994 | Richmond | Dec 1998 | A |
5947954 | Bonaldo | Sep 1999 | A |
6029946 | Doyle | Feb 2000 | A |
6036171 | Weinheimer et al. | Mar 2000 | A |
6041805 | Gydesen et al. | Mar 2000 | A |
6050978 | Orr et al. | Apr 2000 | A |
6063062 | Paradis | May 2000 | A |
6068011 | Paradis | May 2000 | A |
6068617 | Richmond | May 2000 | A |
6079432 | Paradis | Jun 2000 | A |
6106502 | Richmond | Aug 2000 | A |
6113068 | Ryan | Sep 2000 | A |
6142446 | Leinsing | Nov 2000 | A |
6152913 | Feith et al. | Nov 2000 | A |
6168137 | Paradis | Jan 2001 | B1 |
6170522 | Tanida | Jan 2001 | B1 |
6171287 | Lynn et al. | Jan 2001 | B1 |
6189859 | Rohrbough et al. | Feb 2001 | B1 |
6206860 | Richmond | Mar 2001 | B1 |
6221029 | Mathis et al. | Apr 2001 | B1 |
6224578 | Davis et al. | May 2001 | B1 |
6242393 | Ishida et al. | Jun 2001 | B1 |
6245048 | Fangrow et al. | Jun 2001 | B1 |
6290206 | Doyle | Sep 2001 | B1 |
6299132 | Weinheimer et al. | Oct 2001 | B1 |
6325100 | Bunschoten et al. | Dec 2001 | B1 |
6402207 | Segal et al. | Jun 2002 | B1 |
6428520 | Lopez | Aug 2002 | B1 |
6431219 | Redler et al. | Aug 2002 | B1 |
6485472 | Richmond | Nov 2002 | B1 |
6499719 | Clancy et al. | Dec 2002 | B1 |
6508792 | Szames et al. | Jan 2003 | B2 |
6508807 | Peters | Jan 2003 | B1 |
6541802 | Doyle | Apr 2003 | B2 |
6543745 | Enerson | Apr 2003 | B1 |
6581906 | Pott et al. | Jun 2003 | B2 |
6585229 | Cote et al. | Jul 2003 | B2 |
6595964 | Finley et al. | Jul 2003 | B2 |
6595981 | Huet | Jul 2003 | B2 |
6609696 | Enerson | Aug 2003 | B2 |
6612624 | Segal et al. | Sep 2003 | B1 |
6666852 | Niedospial, Jr. | Dec 2003 | B2 |
6673059 | Guala | Jan 2004 | B2 |
6695817 | Fangrow | Feb 2004 | B1 |
6745998 | Doyle | Jun 2004 | B2 |
6808161 | Hishikawa | Oct 2004 | B1 |
6840501 | Doyle | Jan 2005 | B2 |
6843513 | Guala | Jan 2005 | B2 |
6869426 | Ganem | Mar 2005 | B2 |
6875205 | Leinsing | Apr 2005 | B2 |
6893056 | Guala | May 2005 | B2 |
6899315 | Mailville et al. | May 2005 | B2 |
6911025 | Miyahara | Jun 2005 | B2 |
6955669 | Curutcharry | Oct 2005 | B2 |
6964406 | Doyle | Nov 2005 | B2 |
7004934 | Vaillancourt | Feb 2006 | B2 |
7037302 | Vaillancourt | May 2006 | B2 |
7040598 | Raybuck | May 2006 | B2 |
7044441 | Doyle | May 2006 | B2 |
7100891 | Doyle | Sep 2006 | B2 |
7125396 | Leinsing et al. | Oct 2006 | B2 |
7137654 | Segal et al. | Nov 2006 | B2 |
7140592 | Phillips | Nov 2006 | B2 |
7182313 | Doyle | Feb 2007 | B2 |
7195228 | Tiberghien et al. | Mar 2007 | B2 |
7244249 | Leinsing et al. | Jul 2007 | B2 |
7306197 | Parrino et al. | Dec 2007 | B2 |
7306198 | Doyle | Dec 2007 | B2 |
7306566 | Raybuck | Dec 2007 | B2 |
7316679 | Bierman | Jan 2008 | B2 |
7347458 | Rome et al. | Mar 2008 | B2 |
7350764 | Raybuck | Apr 2008 | B2 |
7361164 | Simpson et al. | Apr 2008 | B2 |
7497484 | Ziman | Mar 2009 | B2 |
7559530 | Korogi et al. | Jul 2009 | B2 |
7588563 | Guala | Sep 2009 | B2 |
7628781 | Roy et al. | Dec 2009 | B2 |
7645274 | Whitley | Jan 2010 | B2 |
7651481 | Raybuck | Jan 2010 | B2 |
7666170 | Guala | Feb 2010 | B2 |
7722090 | Burton et al. | May 2010 | B2 |
7758566 | Simpson et al. | Jul 2010 | B2 |
7766304 | Phillips | Aug 2010 | B2 |
7766897 | Ramsey et al. | Aug 2010 | B2 |
7803139 | Fangrow, Jr. | Sep 2010 | B2 |
7803140 | Fangrow, Jr. | Sep 2010 | B2 |
7815614 | Fangrow, Jr. | Oct 2010 | B2 |
7837658 | Cote et al. | Nov 2010 | B2 |
7857805 | Raines | Dec 2010 | B2 |
7875019 | Barron et al. | Jan 2011 | B2 |
7976532 | Kitani et al. | Jul 2011 | B2 |
7998134 | Fangrow et al. | Aug 2011 | B2 |
8066692 | Simpson et al. | Nov 2011 | B2 |
8177772 | Christensen et al. | May 2012 | B2 |
8196614 | Kriheli | Jun 2012 | B2 |
8211069 | Fangrow, Jr. | Jul 2012 | B2 |
8225826 | Horppu et al. | Jul 2012 | B2 |
8262628 | Fangrow, Jr. | Sep 2012 | B2 |
8286936 | Kitani et al. | Oct 2012 | B2 |
8287513 | Ellstrom et al. | Oct 2012 | B2 |
8414554 | Garfield et al. | Apr 2013 | B2 |
8414555 | Garfield et al. | Apr 2013 | B2 |
8454579 | Fangrow, Jr. | Jun 2013 | B2 |
8556868 | Simpson et al. | Oct 2013 | B2 |
8647310 | Fangrow, Jr. et al. | Feb 2014 | B2 |
8679090 | Anderson et al. | Mar 2014 | B2 |
8721628 | Ziman | May 2014 | B2 |
8777908 | Fangrow, Jr. | Jul 2014 | B2 |
8777909 | Fangrow, Jr. | Jul 2014 | B2 |
8864737 | Hasegawa et al. | Oct 2014 | B2 |
8888758 | Mansour et al. | Nov 2014 | B2 |
8899267 | Diodati et al. | Dec 2014 | B2 |
9114242 | Fangrow et al. | Aug 2015 | B2 |
9126028 | Fangrow et al. | Sep 2015 | B2 |
9126029 | Fangrow et al. | Sep 2015 | B2 |
9168366 | Fangrow et al. | Oct 2015 | B2 |
9345641 | Kraus et al. | May 2016 | B2 |
9358379 | Fangrow | Jun 2016 | B2 |
9592344 | Simpson et al. | Mar 2017 | B2 |
9636492 | Fangrow, Jr. | May 2017 | B2 |
9707346 | Simpson et al. | Jul 2017 | B2 |
9724504 | Fangrow, Jr. et al. | Aug 2017 | B2 |
20010029355 | Szames et al. | Oct 2001 | A1 |
20020066715 | Niedospial, Jr. | Jun 2002 | A1 |
20030060804 | Vaillancourt | Mar 2003 | A1 |
20030066978 | Enerson | Apr 2003 | A1 |
20030111623 | Enerson | Jun 2003 | A1 |
20030136932 | Doyle | Jul 2003 | A1 |
20030208165 | Christensen et al. | Nov 2003 | A1 |
20040074541 | Sharpe | Apr 2004 | A1 |
20040124388 | Kiehne | Jul 2004 | A1 |
20040124389 | Phillips | Jul 2004 | A1 |
20040244848 | Maldavs | Dec 2004 | A1 |
20050015075 | Wright et al. | Jan 2005 | A1 |
20050124942 | Richmond | Jun 2005 | A1 |
20050212292 | Parrino et al. | Sep 2005 | A1 |
20050228362 | Vaillancourt | Oct 2005 | A1 |
20050245872 | Simpson et al. | Nov 2005 | A1 |
20060025751 | Roy et al. | Feb 2006 | A1 |
20060058734 | Phillips | Mar 2006 | A1 |
20060065873 | Doyle | Mar 2006 | A1 |
20060129109 | Shaw et al. | Jun 2006 | A1 |
20060142730 | Proulx et al. | Jun 2006 | A1 |
20060142735 | Whitley | Jun 2006 | A1 |
20060149213 | Raybuck | Jul 2006 | A1 |
20060157984 | Rome et al. | Jul 2006 | A1 |
20060161115 | Fangrow | Jul 2006 | A1 |
20060163514 | Doyle | Jul 2006 | A1 |
20060192164 | Korogi et al. | Sep 2006 | A1 |
20060202146 | Doyle | Sep 2006 | A1 |
20060253084 | Nordgren | Nov 2006 | A1 |
20070043334 | Guala | Feb 2007 | A1 |
20070088292 | Fangrow | Apr 2007 | A1 |
20070088293 | Fangrow | Apr 2007 | A1 |
20070088294 | Fangrow | Apr 2007 | A1 |
20070088324 | Fangrow | Apr 2007 | A1 |
20070088327 | Guala | Apr 2007 | A1 |
20070102923 | Niemela | May 2007 | A1 |
20070179453 | Lim et al. | Aug 2007 | A1 |
20080103485 | Kruger | May 2008 | A1 |
20080287920 | Fangrow et al. | May 2008 | A1 |
20080190485 | Guala | Aug 2008 | A1 |
20080290657 | McKeon, III | Nov 2008 | A1 |
20100063482 | Mansour et al. | Mar 2010 | A1 |
20120046636 | Kriheli | Feb 2012 | A1 |
20120089101 | Carlyon et al. | Apr 2012 | A1 |
20120316536 | Carrez et al. | Dec 2012 | A1 |
20130006211 | Takemoto | Jan 2013 | A1 |
20130231616 | Fangrow, Jr. | Sep 2013 | A1 |
20130304037 | Fangrow | Nov 2013 | A1 |
20140020792 | Kraus et al. | Jan 2014 | A1 |
20140246616 | Fangrow | Sep 2014 | A1 |
20150051555 | Fangrow, Jr. | Feb 2015 | A1 |
20160263367 | Fangrow et al. | Sep 2016 | A1 |
20160271327 | Simpson et al. | Sep 2016 | A1 |
20170296801 | Fangrow, Jr. | Oct 2017 | A1 |
20170304547 | Simpson | Oct 2017 | A1 |
20180015275 | Fangrow | Jan 2018 | A1 |
Number | Date | Country |
---|---|---|
2747283 | Jul 2002 | CA |
0 158 030 | Oct 1985 | EP |
0 368 473 | May 1990 | EP |
0 791 371 | Aug 1997 | EP |
0 795 342 | Sep 1997 | EP |
1 946 792 | Jul 2008 | EP |
2 116 277 | Sep 1983 | GB |
2 118 440 | Nov 1983 | GB |
2 353 078 | Feb 2001 | GB |
56-72659 | Jun 1981 | JP |
58-13216 | Jan 1983 | JP |
59-41429 | Mar 1984 | JP |
60-89488 | Jun 1985 | JP |
63-175383 | Nov 1988 | JP |
11-311234 | Nov 1999 | JP |
2001-187990 | Jul 2001 | JP |
2004-000483 | Jan 2004 | JP |
WO 199532748 | Dec 1995 | WO |
WO 200103756 | Jan 2001 | WO |
WO 200123026 | Apr 2001 | WO |
WO 2002096500 | Dec 2002 | WO |
WO 2003013646 | Feb 2003 | WO |
WO 2004060474 | Jul 2004 | WO |
WO 2004082756 | Sep 2004 | WO |
WO 2006020635 | Feb 2006 | WO |
WO 2006076656 | Jul 2006 | WO |
WO 2006088858 | Aug 2006 | WO |
WO 2006124756 | Nov 2006 | WO |
WO 2008144447 | Nov 2008 | WO |
WO 2011139995 | Nov 2011 | WO |
WO 2013036854 | Mar 2013 | WO |
Entry |
---|
U.S. Appl. No. 11/417,648, filed May 3, 2006, Gustus et al. |
U.S. Appl. No. 11/417,671, filed May 3, 2006, Gustus et al. |
U.S. Appl. No. 11/417,882, filed May 3, 2006, Gustus et al. |
U.S. Appl. No. 11/417,909, filed May 3, 2006, Gustus et al. |
U.S. Appl. No. 11/417,923, filed May 3, 2006, Gustus et al. |
U.S. Appl. No. 14/020,579, filed Oct. 22, 2015, Fangrow et al. |
U.S. Appl. No. 15/169,606, filed May 31, 2016, Simpson et al. |
U.S. Appl. No. 15/648,147, filed Jul. 12, 2017, Simpson et al. |
U.S. Appl. No. 15/669,786, filed Aug. 4, 2017, Fangrow et al. |
Air Embolism and Exsanguination from Separation of Two-Piece Side Port/Hemostasis Valve Cardiac Catheter Introducers, ECRI Institute, Jan. 1995, in 2 pages, http://www.mdsr.ecri.org/summary/detail.aspx?doc_id=8098. |
Injection Site, Molded Products, Inc., Apr. 2, 2004, in 1 page, https://web.archive.org/web/20040402123354/https://www.moldedproducts.com/injectionsite.htm. |
EPO Search Report re EP Application No. 08 755 612.2, dated Feb. 23, 2012 in 5 pages. |
EPO Examination Report re EP Application No. 08 755 612.2, dated Nov. 20, 2013 in 5 pages. |
EPO Examination Report re EP Application No. 08 755 612.2, dated Dec. 5, 2012 in 6 pages. |
International Search Report for PCT/US2006/026124, dated Mar. 3, 2007 in 5 pgs. |
International WrittenOpinion for PCT/US2006/026124, dated Jan. 10, 2008 in 11 pgs. |
International Search Report and Written Opinion of International Application No. PCT/US2008/063797 dated Dec. 30, 2008 in 21 pages. |
International Preliminary Report on Patentability, International Application No. PCT/US2008/063797 dated Nov. 17, 2009 in 11 pages. |
Number | Date | Country | |
---|---|---|---|
20180036524 A1 | Feb 2018 | US |
Number | Date | Country | |
---|---|---|---|
60707319 | Aug 2005 | US | |
60696894 | Jul 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15499740 | Apr 2017 | US |
Child | 15789242 | US | |
Parent | 15091484 | Apr 2016 | US |
Child | 15499740 | US | |
Parent | 14329372 | Jul 2014 | US |
Child | 15091484 | US | |
Parent | 13534663 | Jun 2012 | US |
Child | 14329372 | US | |
Parent | 12893789 | Sep 2010 | US |
Child | 13534663 | US | |
Parent | 11482176 | Jul 2006 | US |
Child | 12893789 | US |